Interleukin-18 expression increases in response to neurovascular damage following soman-induced status epilepticus in rats by Erik A. Johnson et al.
Johnson et al. Journal of Inflammation  (2015) 12:43 
DOI 10.1186/s12950-015-0089-9RESEARCH Open AccessInterleukin-18 expression increases in
response to neurovascular damage following
soman-induced status epilepticus in rats
Erik A. Johnson1*, Michelle A. Guignet1, Thuy L. Dao1, Tracey A. Hamilton2 and Robert K. Kan1Abstract
Background: Status epilepticus (SE) can cause neuronal cell death and impaired behavioral function. Acute exposure
to potent acetylcholinesterase inhibitors such as soman (GD) can cause prolonged SE activity, micro-hemorrhage and
cell death in the hippocampus, thalamus and piriform cortex. Neuroinflammation is a prominent feature of brain
injury with upregulation of multiple pro-inflammatory cytokines including those of the IL-1 family. The highly
pleiotropic pro-inflammatory cytokine interleukin-18 (IL-18) belongs to the IL-1 family of cytokines and can
propagate neuroinflammation by promoting immune cell infiltration, leukocyte and lymphocyte activation, and
angiogenesis and helps facilitate the transition from the innate to the adaptive immune response. The purpose
of this study is to characterize the regional and temporal expression of IL −18 and related factors in the brain
following SE in a rat GD seizure model followed by localization of IL-18 to specific cell types.
Methods: The protein levels of IL-18, vascular endothelial growth factor and interferon gamma was quantified in
the lysates of injured brain regions up to 72 h following GD-induced SE onset using bead multiplex immunoassays.
IL-18 was localized to various cell types using immunohistochemistry and transmission electron microscopy. In
addition, macrophage appearance scoring and T-cell quantification was determined using immunohistochemistry.
Micro-hemorrhages were identified using hematoxylin and eosin staining of brain sections.
Results: Significant increases in IL-18 occurred in the piriform cortex, hippocampus and thalamus following SE. IL-18
was primarily expressed by endothelial cells and astrocytes associated with the damaged neurovascular unit. The
increase in IL-18 was not related to macrophage accumulation, neutrophil infiltration or T-cell appearance in the injured
tissue.
Conclusions: These data show that IL-18 is significantly upregulated following GD-induced SE and localized
primarily to endothelial cells in damaged brain vasculature. IL-18 upregulation occurred following leukocyte/
lymphocyte infiltration and in the absence of other IL-18-related cytokines, suggesting another function,
potentially for angiogenesis related to GD-induced micro-hemorrhage formation. Further studies at more
chronic time points may help to elucidate this function.
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Exposure to chemical warfare nerve agents (CWNA),
such as soman (pinacolyl methylphosphonofluoridate,
GD), causes a myriad of negative physiological events
related to excess acetylcholine accumulation to include
intense tonic-clonic convulsions, acute morbid hyperten-
sion, and potentially death [1–3]. In the brain, nerve
agent exposure causes status epilepticus (SE) [4] leading
to excitotoxic brain injury, neuroinflammatory gliosis,
neutrophil infiltration, expression of pro-inflammatory
factors and widespread neuronal cell loss observed in
the piriform cortex, hippocampus, amygdala and thal-
amus [5–8]. In addition, acute hypertension can damage
capillaries, further exacerbating brain injury. In response,
innate inflammatory processes occur to include upregu-
lation of interleukin-1 (IL-1) family cytokines (IL-1α and
β), leukocyte chemotaxis factors (CXCL1 and MIP-1α)
and leukocyte recruitment in injured brain regions [8, 9].
IL-18 is a member of the IL-1 family of cytokines that is
involved in both innate and adaptive immune responses
and helps transition a non-specific inflammation reaction
to a directed lymphocyte response [10]. Because of this
pleiotropic nature, IL-18 has been implicated in several
injury-related processes including immune cell activation,
propagation of the adaptive immune response and vascu-
lar repair.
Unlike most pro-inflammatory cytokines, IL-18 ap-
pears to be constitutively expressed in the brain [11–13].
However, IL-18 significantly increases expression in
damaged brain cells such as neurons [14] and endothe-
lial cells [15], and injury response cells such as astrocytes
[14, 16], microglia [16, 17], macrophages [18] and infil-
trating monocytes [19] in response to various brain in-
sults including seizure [14, 20, 21]. IL-18 is particularly
involved in guiding and activating circulating immune
cells to injured tissues. IL-18 can induce factors involved
in neutrophil chemotaxis such as CXCL1 and leukotri-
ene B4 [22, 23] and can upregulate various cellular adhe-
sion molecules on monocytes [22, 24], T-cells [25] and
endothelial cells [15, 22, 26] to facilitate rolling and vas-
cular infiltration. IL-18 expression promotes immune
cell activation by inducing the expression of multiple
pro-inflammatory cytokines, chemokines and prolifera-
tive factors in activated macrophages [27–29], microglia
[17], CD4(+) T-cells [28], B cells [30], natural killer (NK)
cells [31, 32], CD8+ lymphocytes [17] and neutrophils
[23]. IL-18 plays an important role in transitioning
innate inflammation to the adaptive immune response
by providing an early signal for development of Th1
lymphocyte responses [33] and by helping regulate func-
tionally distinct subsets of T-helper cells required for
cell-mediated immune responses [34]. In conjunction
with IL-12 [32], IL-18 expression enhances the adaptive
immune response particularly through increased expressionand release of interferon gamma (IFNγ) by T- and NK cells
[31], which in turn upregulates and promotes Fas-mediated
apoptosis [35]. Lastly, IL-18 also affects angiogenesis
through induction of vascular endothelial growth factor
(VEGF) [36] and by stimulating endothelial cell prolifera-
tion and chemotaxis to repair damaged blood vessels [37].
In conjunction with IL-12, IL-18 can also upregulate angio-
genic and angiostatic chemokines, which also contribute to
the wound healing process [38].
While early innate mechanisms of inflammation have
been investigated following seizurogenic nerve agent ex-
posure, IL-18 is unique as an immune transition cytokine
to a directed adaptive response. Lymphocyte infiltration
following ‘sterile’ neuroinflammation (i.e., inflammation
not caused by infection) has been reported following vari-
ous CNS injuries including acute ischemic damage [39],
though the exact role these cells play in models of injury
is not well understood. However, a lack of T-cell response
(both CD4+ and CD8+) can attenuate brain damage in
various CNS injury models [40]. Because of the ‘sterile’ na-
ture of GD-induced seizure injury, it is not clear whether
IL-18 plays a role in the progression of the inflammatory
response to a more chronic response following nerve
agent exposure or whether it has a more specific role in
acute response to injury (e.g., leukocyte infiltration).
Therefore, the purpose of this study was to investigate IL-
18 upregulation and related factors (i.e., VEGF, IFNγ and
T-cell related interleukins) following GD exposure, using
multiplex bead immunoassay and immunohistochemistry.
Further studies were conducted to localize IL-18 expres-
sion to areas of vascular injury and to investigate the
innate to adaptive immune response transition using
macrophage and T-cell infiltration into injured brain
areas. These data are the first to show IL-18 upregulation
and cellular origin along with expression of other
innate-to-adaptive immune response factors following
GD-induced SE.
Methods
Animals and GD Seizure Model
Adult male Sprague–Dawley rats (Charles River Labora-
tories, Wilmington, MA; CRL: CD[SD]-BR, 250–350 g)
were treated with HI-6 dichloride (Walter Reed Army
Institute of Research, Silver Spring, MD; 125 mg/kg, i.p.)
30 min prior to GD administration and with atropine
methyl nitrate (AMN, Sigma-Aldrich, St. Louis, MO;
2.0 mg/kg, i.m.) 1 min after GD administration. Vehicle
control animals received HI-6, AMN and saline, while
naïve animals received no injections. GD (GD-U-2323-
CTF-N, purity 98.8 wt%) was diluted in saline at the
USAMRICD. GD (180 μg/kg) was administered subcuta-
neously in the scruff of the neck, and the rat was ob-
served for convulsive activity. This dose of GD produces
a 100 % generalized convulsive seizure rate within
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perimental protocol was approved by the Animal Care
and Use Committee at the United States Army Medical
Research Institute of Chemical Defense and all proce-
dures were conducted in accordance with the principles
stated in the Guide for the Care and Use of Laboratory
Animals (National Research Council, 2011), and the
Animal Welfare Act of 1966 (P.L. 89–544), as amended.
The animal care program at this institute is fully accre-
dited by the Association for Assessment and Accreditation
of Laboratory Animal Care, International.
Multiplex bead array immunoassay
Experimental and vehicle control animals were euthanized
with a sodium pentobarbital solution (65–100 mg/kg, i.p.)
at 0.5, 1, 3, 6, 12, 24, 48 or 72 h after onset of convulsions;
naïve animals were euthanized at 24 h only. Following eu-
thanasia, the brains were removed, dissected and proc-
essed into lysate as previously described [9]. Briefly, the
piriform cortex, hippocampus and thalamus were excised,
rinsed with cold PBS and snap frozen in liquid nitrogen.
The tissues were weighed and homogenized in ice-cold
triple detergent lysis buffer containing a Complete™ prote-
ase inhibitor cocktail (Roche Biochemicals, Indianapolis,
IN) at a ratio of 1 ml buffer to 50 mg tissue. Samples were
allowed to stand at 4 ° C for at least 30 min before centri-
fugation at 8000 G for 5 min and removal of the lysate for
assaying. IL-18, VEGF and IFNγ concentrations were
quantified using a rat cytokine multiplex bead immuno-
assay kit (EMD Millipore, St. Charles, MO). Concentra-
tions of IL-4, IL-10, IL-12 and IL-17 were run in parallel
and previously reported [8]. The bead immunoassay pro-
cedure used 25 μl of lysate (94 ± 8 μg protein) per well
and was conducted according to the manufacturer’s in-
structions. The plate was read on a Luminex™ 100 in-
strument (Bio-Rad Laboratories, Hercules, CA) and
analyzed with either BioRad or STaRStation software
(Applied Cytometry, Sacramento, CA). Experimental
and naïve group numbers were ≥5 for all brain regions
and time points except for the experimental 6 h (n = 4)
and 12 h (n = 3) thalamus. Time-matched vehicle con-
trols (n = 3 per time point) were analyzed individually
and pooled into a single vehicle control comparison
group when no significant difference was found
between these samples over time by analyte or brain
region (data not shown).
Immunohistochemistry (IHC)
Separate from the animals used in the multiplex bead
array immunoassay, experimental, vehicle control and
naïve animals were deeply anesthetized and perfused
with cold isotonic saline followed by 4 % paraformalde-
hyde via cardiac puncture. Brains were moved to 4 %
formaldehyde for 6–8 h, then allowed to sit in 30 %sucrose/PBS at 4 ° C for another 12–16 h. Tissues were
then blocked, cut on a Leica CM3050 S cryostat
(Thermo Shandon, Inc.; Pittsburgh, PA) at 40 μm and
stored in cryobuffer (30 % each of glycerol, ethylene gly-
col and water, 10 % 2 × phosphate buffer) until use. Free
float fluorescent IHC labeling was conducted as previ-
ously described [43]. Experimental and vehicle control
samples had an n = 4 for each cytokine/cell type combin-
ation. The antibodies used were as follows: rabbit anti-
IL-18 (1:250; sc6179, Santa Cruz Bio, Santa Cruz, CA),
mouse anti-NeuN (1:1000; MAB377, Chemicon, Temec-
ula, CA), mouse anti–glial fibrillary acidic protein
(GFAP)(1:1000; MS-280-P, NeoMarkers, Fremont, CA),
mouse anti-cd11b (1:1000; CBL1512, Chemicon), mouse
anti-rat endothelial cell antigen (RECA)(1:1000; ab9774,
Abcam), mouse anti-von Willebrand factor (vWf)(1:100;
MAB3442, Chemicon), rabbit anti-smooth muscle alpha
actin (1:250, Abcam), and mouse anti-NG2 chondroitin
sulfate (1:500; MAB5384, Millipore). For anti-NeuN,
anti-GFAP, anti-cd11b, anti-RECA, anti-von Willebrand
factor, anti-smooth muscle alpha actin and anti-NG2
chondroitin sulfate, a species-appropriate Alexafluor™
594 fluorescent-tagged secondary (1:1000, Molecular
Probes; Eugene, OR) was used for visualization. For anti-
IL-18, a biotin-labeled secondary (1:1000, Vector Labora-
tories; Burlingame, CA) followed by an Alexafluor™ 488
fluorescent-tagged tertiary antibody (1:1000, Molecular
Probes) was used for signal amplification. Tissue sections
labeled with only secondary and tertiary antibodies were
used as controls. All sections used were located between
interaural 6.20 mm, bregma −2.80 mm and interaural
5.20 mm, bregma −3.80 mm [44]. For experiments re-
quiring cell counting, investigators were blinded from
the conditions. Sections were viewed and digitally cap-
tured with an Olympus BX51 microscope equipped
with an Olympus DP-70 high-resolution color CCD
digital camera. An Olympus BX61 equipped with a
DSU spinning disk confocal system and DP-70 CCD
camera was used to confirm same cell co-localization.
Images of 40 μm tissues were acquired using a z step
interval of 1 μm and analyzed using Slidebook™ soft-
ware. Publication images were compiled using Adobe
Photoshop CS4 digital image software. To more easily
view the nuclei in 10x photomicrographs, the blue
channel had the unsharpen mask filter applied with the
following parameters: Amount = 500 %, Radius = 2.6 pixels,
Threshold = 13 levels. For all photomicrographs, color
levels were evened using the ‘levels’ tool. Input levels
(0–255) were normalized in the RGB channel as follows:
highlight input levels were set at the peak of the image
histogram (10x and 40x), midtone levels were set at 0.8
(10x and 40x) and shadow levels were set at 75 (10x) or
at the edge of the histogram closest to 255 or at 180,
whichever was greater (40x).
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Free floating brain sections approximately 40 μm
thick were labeled with rabbit anti-IL-18 and biotinyl-
ated anti-rabbit IgG secondary as described above
and incubated in avidin-biotin-peroxidase complex
solution (Life Technologies; Grand Island, NY) at room
temperature for 30 min and finally with SIGMAFast™
3,3′-diaminobenzidine (DAB; Sigma-Aldrich, St. Louis,
MO) solution for desired stain intensity. Regions of inter-
est were excised from the tissue, buffer-washed, post-fixed
in buffered 1 % osmium tetroxide, dehydrated in graded
ethanol and embedded in PolyBed® epoxy resin (Poly-
sciences Inc., Warrington, PA). Ultrathin tissue sections
approximately 90 nm thick were mounted on copper
mesh grids. Imaging was performed using a JEOL JEM-
1230 transmission electron microscope (JEOL USA Inc.;
Peabody, MA).
Histology for micro-hemorrhage
Tissue samples were fixed in 10 % formalin, dehy-
drated in a series of alcohol washes, cleared in a xy-
lene substitute (Micro-Clear, Micron Environmental
Industries, Alexandria, VA) and embedded in paraffin.
Sections were cut at 5 μm, stained with hematoxylin
and eosin (H&E) using the Leica ST5020 Multistainer -
CV5030 Coverslipper integrated workstation (Leica
Biosystems Inc., Buffalo Grove, IL) and digitally
captured using the Nanozoomer 2.0RS slide scanner
(Olympus). Micro-hemorrhage was defined as ≥5
red blood cells found in the tissue around a blood
vessel.Fig. 1 IL-18 is expressed in the rat brain following GD-induced SE. Concen
thalamus (open gray line), while the highest concentration in the piriform
lysate and reported as mean ± SEM. Statistical comparisons were to vehicle
Bonferroni’s analysis. (# p < 0.05 hippocampus, * p < 0.05 piriform cortex, $Macrophage appearance scoring
Sections from vehicle control and experimental time
points at 0.5, 1, 3, 6, 12, 24 and 48 h after onset of con-
vulsions labeled with anti-cd11b (described above) were
used for this analysis. Three representative 10x micro-
graphs (2.44 × 1.06 μm2) were taken from ≥ 3 animals
for each brain region/animal; the median was used for
data analysis. Macrophages were identified as a cell hav-
ing ameboid morphology, showing a predominant loss
of processes and being positive for cd11b. A macrophage
scoring system was developed based on number of mac-
rophages present per micrograph. Criteria for scoring
were as follows: Score (0), No ameboid cells present;
Score (1), 1–10 ameboid cells present throughout 10x
photomicrograph; Score (2), 11–29 ameboid cells present
throughout 10x photomicrograph; and Score (3), >30
ameboid cells present throughout 10x photomicrograph.
Origin of macrophages, either central or peripheral, was
not determined.
T-cell quantification
Sections from vehicle control and experimental time
points 6, 12, 24, 48 and 72 h after onset of convulsions
were labeled with mouse anti-rat pan T-cell marker
(1:100; sc-52711, Santa Cruz) and visualized with DAB.
Images were visualized and captured as described above.
Bilateral representative 10x micrographs (2.44 × 1.06 μm2)
were taken for each brain region/animal with each time
point having an n =3. T-cells were quantified using
Visiopharm software by counting positively labeled
cells per region/mm2. Counts were divided by cellstrations of IL-18 peak at 48 h in the hippocampus (solid black line) and
cortex (solid gray line) is at 72 h. Data are given as pg/ml of tissue
controls within each brain region using ANOVA with a post-hoc
p < 0.05 thalamus)
Fig. 2 IL-18 expression is associated with vascular structures in injured
brain regions. Tissue sections at 48 h were labeled with anti-IL-18
antibody along with cell type-specific antibodies. IL-18 immunolabeling
(a-i, green) is present in the piriform cortex, hippocampus and thalamus
following GD-induced SE (a, b & c; left) but absent in vehicle controls
(a, b & c; right). IL-18 labeling was associated with the neurovascular
unit, though labeling was predominantly co-incident with these
immunolabels. Neurons (d, red) and vasculature-associated astrocytes
(e, red) had rare and non-contiguous co-localization. Labeling was
absent in microglia (f, red) and smooth muscle (g, red). Consistent
co-incident labeling of IL-18 was present near pericytes (h, red) and
endothelial cells (i, red). DAPI (a-h, blue) was used to label the nuclei of
cells. (Scale bar: 250 μm [a-c], 50 μm for fluorescent and 5 μm [d-i] for
confocal microscopy; n = 3 for 48-h, n = 4 for vehicle controls)
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that had infiltrated into the tissue.
Statistical analysis
Temporal changes in immunoassay data and T-cell
quantification were evaluated by ANOVA with a post-
hoc Bonferroni’s analysis. Macrophage appearance
scores were evaluated using a Kruskal-Wallis test
followed by a post-hoc Dunn’s Multiple Comparison
test. Pearson’s correlation coefficients were calculated
for macrophage appearance scoring, and T-cell quanti-
fication data compared to IL-18 concentration data.
Values are expressed as mean ± SEM. For immuno-
assay data, points calculated below the minimum de-
tectible concentrations (MinDC) for the assays were
conservatively set at −0.01 pg/ml of the MinDC for
statistical analyses. Differences were considered signifi-
cant at the level of p ≤ 0.05. All statistics were analyzed
using GraphPad Prism v5.04 for Windows.
Results
IL-18 is significantly upregulated in the brain following
GD-induced seizure
Temporal and regional changes in IL-18, IFNγ and
VEGF protein concentrations were determined using a
bead-based multiplex immunoassay on tissue lysates
from the piriform cortex, hippocampus and thalamus.
IL-4, IL-10, IL-12 and IL-17 protein concentrations were
investigated in previous experiments and did not signifi-
cantly change [8]. Additionally, no significant changes
were observed for IFNγ or VEGF in this experiment
(data not shown). Significant changes in IL-18 concentra-
tions were observed in the piriform cortex, hippocampus
and thalamus up to 72 h following GD-induced seizure
compared to vehicle controls (Fig. 1). The highest concen-
trations were in the hippocampus, where concentrations
significantly increased by 24 h (1030 ± 197 pg/ml) and
peaked by 48 h (1471 ± 197 pg/ml vs. 488 ± 30 pg/ml in
vehicle controls) following GD-induced SE. In the piri-
form cortex, IL-18 levels were significantly elevated by
48 h (895 ± 78 pg/ml) and continued to rise through
72 h (1060 ± 28 pg/ml) compared to vehicle controls
(521 ± 80 pg/ml). In the thalamus, IL-18 concentration
peaked at 48 h (1039 ± 199 pg/ml) and was still signifi-
cantly greater at 72 h (829 ± 128 pg/ml) compared to
vehicle controls (290 ± 19 pg/ml).
IL-18 is expressed primarily by endothelial cells in injured
brain regions
Forty-eight hours following GD-induced SE, IL-18
immuno-labeling was present in the piriform cortex
(Fig. 2a, left), hippocampus (Fig. 2b, left) and thalamus
(Fig. 2c, left). Specific labeling was largely absent in ve-
hicle controls (Fig. 2a-c, right), though some sporadiclabeling was observed in the piriform cortex. No specific
labeling was observed with secondary-only or second-
ary/tertiary-only controls (data not shown).
While some IL-18 labeling was observed in NeuN-
positive neuronal populations in layer II of the piriform
cortex (Fig. 2d), pyramidal neurons in the CA3 hippo-
campus, pyramidal and extrapyramidal neurons of the
dentate gyrus and in neurons of the dorsolateral thal-
amus, the majority of IL-18 labeling was found in and
around cells of the neurovascular unit. However, strict
co-localization with cell type markers was sporadic and
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proximity, typically adjacent). Few instances of co-
localization were observed between IL-18 and GFAP-
positive astrocytes (Fig. 2e), while no co-localization was
found with cd11b-positive microglia (Fig. 2f ) or smooth
muscle labeled with actin (Fig. 2g). IL-18 appeared to be
expressed by NG2 chondroitin sulfate-positive pericytes
(Fig. 2h) and/or RECA-positive endothelial cells (Fig. 2i)
because of the vascular morphology displayed by IL-18
and strong co-incident labeling with RECA, an antigen
found only on the luminal side of endothelial cells. To
confirm cell type expression of IL-18, transmission elec-
tron microscopy was used. IL-18 was only found within
cells identified phenotypically as endothelial cells (Fig. 3a),
typically around regions of vascular injury. IL-18 was pri-
marily expressed in a defined layer towards the apical re-
gion of the endothelial cell (Fig. 3b) but could also be
identified as diffuse labeling within the cell (Fig. 3c) and
between the intracellular junctions (Fig. 3d).
IL-18 is associated with GD-induced vascular damage
Following GD exposure, numerous capillary hemor-
rhages were observed by H&E staining in all damaged
brain regions, though most prominently in the thalamicFig. 3 IL-18 is expressed primarily by endothelial cells. Transmission electron
associated with endothelial cells (a-d). Expression was observed around dama
in the cell body (c) and at intracellular junctions of endothelial cells (d). (ec =
1 μm [a], 0.2 μm [b-d]; n = 3)nuclei, starting at 3 h and persisting up to 72 h after
seizure onset (Fig. 4a). No micro-hemorrhages were ob-
served in vehicle controls (Fig. 4b). Damage was also vi-
sualized with an antibody to von Willebrand factor
(vWf), a protein that binds to exposed collagen in endo-
thelial cells in regions of vascular damage and is a more
sensitive marker of vascular injury. IL-18 and vWf label-
ing were present in exposed piriform cortex (Fig. 4c)
and absent in control brains (Fig. 4d). Fewer instances of
vWf positive labeling were observed in the hippocampus
and thalamus, consistent with H&E, though prominent
IL-18 positive labeling was found in both of these re-
gions. IL-18 and vWf labeling were often co-incident
and co-localized to the same continuous vascular struc-
ture (Fig. 4e), though each protein could also readily be
found localized to a vascular structure without the other
present.
IL-18 expression positively correlates with macrophage
accumulation but not T-cell infiltration
IL-18 plays a role in monocyte infiltration and macro-
phage activation [22, 24, 27–29]. Therefore, the appear-
ance of macrophages was scored in each brain region
and correlated to the expression of IL-18 (Fig. 5).microscopy images of damaged piriform cortex shows IL-18 expression
ged endothelial connections (a, open arrow), on the luminal surface (b),
endothelial cell, bl = basal lamina, ij = intracellular junction. Scale bar:
Fig. 4 IL-18 expression is associated with vascular damage. GD exposure causes vascular damage and capillary micro-hemorrhages primarily in
the thalamus (a), though it is also present in other brain regions. Multiple micro-hemorrhages were identified by areas of red blood cell infiltration
in the tissue around capillaries (black arrows and inset). Vascular injury is absent in vehicle controls (b). Immunolabeling for the more sensitive
endothelial cell injury protein, von Willebrand factor (vWf, red), showed extensive damage in the piriform cortex (c) and other brain regions after
GD exposure along with IL-18 (green), but both were absent in vehicle controls (d). IL-18 and vWf labeling were often co-incident to the same
vascular structures, though co-localization was rare (e), consistent with IL-18 expression in endothelial cells. (Scale bar: 250 μm [a-d], 50 μm for
fluorescent [e]; n = 3 for 48-h, n = 4 for vehicle controls)
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following seizure onset in the piriform cortex (Fig. 5a),
thalamus (Fig. 5b), and dentate gyrus (Fig. 5E). Signifi-
cant macrophage accumulation begins in the CA1
(Fig. 5c) and CA3 (Fig. 5d) regions of the hippocampus
at 48 h. No significant accumulation of macrophages
was observed at earlier time points (data not shown).
Significant Pearson’s correlation coefficients indicate that
IL-18 expression and macrophage appearance were
highly correlated in all brain regions investigated(Fig. 5f ). However, significant macrophage accumulation
precedes significant IL-18 expression in the three most
injured regions (i.e., piriform cortex, thalamus and den-
tate gyrus).
T-cell infiltration into injured tissues was quantified in
each brain region because of the ability of IL-18 to in-
crease T-cell adhesion to endothelial cells associated
with injury [25] (Fig. 6). A significant accumulation of
T-cells occurred in the thalamus (Fig. 6a, open gray
line), CA1 (Fig. 6b, open black line), CA3 (Fig. 6b, black
Fig. 5 Macrophage appearance precedes significant IL-18 expression in damaged brain regions. Macrophages significantly appear at 24 h following
seizure onset in the piriform cortex (a), thalamus (b), and dentate gyrus (e). Macrophages in the CA1 (c) and CA3 (d) significantly increase by 48 h.
Pearson’s analysis shows a positive correlation between IL-18 expression and macrophage appearance in the CA1, CA3 and dentate gyrus regions of
the hippocampus, thalamus and piriform cortex (f). Data are given as a macrophage appearance score and reported as median ± Q1 and Q3 and were
analyzed using a Kruskal-Wallis test with a post-hoc Dunn’s Multiple Comparison test. (n = 3 or 4 for each time point/ brain region; * p < 0.05,
** p < 0.01)
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increases in T-cells were also seen in the piriform cortex
(Fig. 6a, gray line), these were not significant. T-cells
bound to the luminal side of the vasculature were also
quantified, though no significant changes were observed
(data not shown). IL-18 expression and T-cell infiltration
are not significantly correlated in any brain region
(Fig. 6c).
Discussion
IL-18 is a unique pro-inflammatory cytokine that has been
implicated in multiple facets of the neuroinflammatory re-
sponse to include innate-to-adaptive immune response
transitions, angiogenesis and leukocyte/lymphocyte infil-
tration. The function of IL-18 is still not well understoodand is likely injury-specific; IL-18 expression appears to
exacerbate pathology in some CNS injury models [45, 46]
and reduce pathology in others [14, 21, 47, 48]. This study
shows that IL-18, like other IL-1 family members [8], is
expressed in response to GD-induced pathogenic seizure
activity and vascular injury. IL-18 expression was promin-
ent following GD-induced brain injury in the three brain
regions investigated and peaked later than other IL-1 fam-
ily members in this model [8]. The timing of expression is
consistent with other studies including models of seizure
induced by kainic acid (KA) [20], hypoxia-ischemia [45],
traumatic brain injury [46] and neurovirulent influenza A
virus infection [49]. However, in this study, IL-18 protein
primarily localized to endothelial cells, perhaps as a result
of pervasive neurovascular injury caused by GD exposure,
Fig. 6 T-cell infiltration precedes significant IL-18 expression in
damaged brain regions. Significant T-cell infiltration was observed at
24 h following GD-induced seizure activity in thalamus (a, open gray
line), the CA1 (b, open black line), CA3 (b, solid black line) and
dentate gyrus (b, black/gray line) though not in the piriform cortex
(solid gray line, a). Increased T-cell infiltration preceded significant
IL-18 expression, and no positive correlation was found between the
two in any brain region (c). Data are given as cells/mm2 of tissue
and reported as mean ± SEM and analyzed using a Kruskal-Wallis test
with a post-hoc Dunn’s Multiple Comparison test. (n = 3 for each
time point/ brain region; A: $ p < 0.05 thalamus, B: $ p < 0.05 CA1,
# p < 0.05 CA3, ** p < 0.01 dentate gyrus)
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ducers of IL-18 in other CNS injury models [20, 45].
Previous studies have indirectly suggested a vascular
injury component to CWNA exposure likely caused by
hypertension and hypoxia [2, 50–52] and resolved by
delayed angiogenesis via VEGF upregulation [53]. This
study has shown that seizurogenic exposure to GD re-
sults in brain micro-hemorrhages and von Willebrand
factor expression after GD exposure. IL-18 expression in
response to these injuries can facilitate vascular repairby upregulating VEGF, stimulating new endothelial cell
proliferation and chemotaxis to injured vessels [22, 36, 37].
Injury to the vasculature appears to stimulate expres-
sion of IL-18 in endothelial cells in this model as part
of the angiogenic process after GD exposure [53].
VEGF, however, was not detected in the first 3 days
after GD-induced injury in this model contrary to
previous studies in mice [53]. However, it cannot be
discounted that VEGF may appear just beyond the
time course studied to increase mature blood vessel
formation months after inury [53]. While outside the
scope of this study, later time points may elucidate
more of this potential function.
Activated microglia can migrate to injured and dying
neurons following GD-induced seizure [9], though this
study found little evidence of microglial or macrophage
expression of IL-18 even as significant numbers of mac-
rophages began to appear in the injured tissue. Because
resident macrophages (i.e., from microglial lineage) are
the first to respond and migrate to areas of injury before
IL-18 expression, it is unlikely that this cytokine is
required for chemotaxis during acute injury. However,
IL-18 may be promoting monocyte infiltration and/or
macrophage activation at the site of injury at later time
points [45, 54]. Additionally, neurons express IL-18 re-
ceptor in response to injury [45], including seizure activ-
ity [14], and can increase IFNγ expression as a result of
IL-18 signaling [49]. However, it is unlikely that IL-18
expression affects neurons shortly after injury as no in-
creases in IFNγ were observed in the injured brain re-
gions. While it is possible that IL-18 expression may
originate from macrophages as the neuroinflammatory
cascade progresses and this may affect IFNγ expression
in neurons, the expression observed in this model ap-
pears to be in response to primary vascular injury.
Immune cell infiltration allows circulating phagocytic
cells such as neutrophils and monocytes to enter the
brain and begin to remove debris as one of the first steps
of the healing process. Lymphocytes, particularly CD4+
and CD8+ T-cells, can also enter the injured brain and
can influence injury resolution even during ‘sterile’
inflammation [40]. IL-18 can facilitate infiltration of
multiple circulating immune cells through the BBB
including monocytes [19, 22, 24], neutrophils [22, 23],
and T-cells [25]. In addition, infiltration is augmented
through cell adhesion molecule expression on endothe-
lial cells [15, 22, 26]. This study shows that neutrophil
infiltration occurs in injured brain regions following sei-
zurogenic nerve agent exposure. However, increases in
neutrophil infiltration and CXCL1 expression precede
significant expression of IL-18, which does not correlate
with neutrophil infiltration (except in the thalamus) or
with CXCL1 expression. In contrast, previous studies
have shown that CXCL1 positively correlates to
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addition, T-cells respond to the primary excitotoxic
injury within the first 24 h, though this is also prior to
significant IL-18 expression. While IL-18 may be in-
volved in T-cell activation, the rapid reduction in T-cells
in the injured tissue by 48 h and the distinct lack of all
primary T-cell expressed factors such as IL-4, IL-10, IL-
12, IL-17 and IFNγ [8] suggest that these cells do not
become activated or participate substantially in the pro-
gressive lesion formation seen in this model at the time
points investigated. It is unlikely that IL-18 contributes
to these acute events in this model since both neutro-
phils and T-cells infiltrate into the tissue prior to signifi-
cant IL-18 expression. However, IL-18 can induce
neutrophils to produce a myriad of inflammatory factors
and may play a role in activation after 72 h once the
cells have infiltrated the injured tissues [23].
Conclusions
This study showed a significant increase in IL-18 in
brain regions injured by excitotoxic seizure activity,
starting as early as 24 h after GD exposure. IL-18
expression largely originated from endothelial cells
particularly those around areas of vascular damage. The
expression significantly correlates with the appearance of
activated macrophages in the brain but not to T cells or,
from previous data, neutrophils. This study did not find
evidence that IL-18 is integrally involved in a propaga-
tion of the adaptive immune response in the time frame
investigated and may therefore be primarily contributing
to amplification of the acute innate inflammatory re-
sponse. In addition, this expression may be part of the
angiogenic mechanism to repair damaged vasculature
caused by micro-hemorrhage formation in the brain in
response to GD exposure though this mechanism does
not appear to be active concurrent with IL-18 expression.
Expression of IL-18 within the first 48 h may therefore be
related to leukocyte infiltration and/or delayed angiogen-
esis, though further studies are needed to elucidate this
role.
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